Immunic
Open
$13.95
Prev. Close
$13.99
High
$13.95
Low
$13.75
Market Snapshot
$180.82M
-1.7
-1.00
92
Immunic Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 92 full-time employees. The company went IPO on 2014-04-17. Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The firm is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
Immunic Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 92 full-time employees. The company went IPO on 2014-04-17. Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The firm is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
Recently from Cashu
Immunic's Strategic Conference Engagements to Promote Neurologic Disease Therapies and Collaborations
Immunic Inc (Ticker: IMUX), a biotechnology company at the forefront of developing oral therapies for neurologic diseases, is actively engaging with the medical and investment community through its up…
Immunic Names Erik Lundgren CEO Amid Significant Advances in MS Therapy Development
Immunic Inc. (Ticker: IMUX) has secured Erik Lundgren as its new Chief Executive Officer, effective May 22, 2026, marking a significant transition for the biotechnology company focused on innovative o…
Immunic Appoints Michael W. Bonney as Board Chair to Advance MS Treatment Development
Immunic, Inc. (Ticker: IMUX) has recently appointed Michael "Mike" W. Bonney as Chair of its Board of Directors, a move anticipated to have significant implications for the company's future, particula…
Immunic Advances Clinical Trials and Implements Reverse Stock Split Amidst Market Challenges
Immunic, Inc. (NASDAQ:IMUX) is advancing its mission to deliver innovative therapies for autoimmune diseases and cancers, with a major focus on its leading candidate, vidofludimus calcium (IMU-838). C…